Articles Tagged With:
-
How to Educate the Board on Quality and Safety as QAPI Expects
The Quality Assessment and Performance Improvement (QAPI) program from the Centers for Medicare & Medicaid Services specifies that hospital boards are responsible for oversight of the QAPI program and that hospital administrators are responsible for educating the board on quality and safety issues. But how does a risk manager educate and update the board on these issues?
-
Risk Managers Valued in Compliance Program Guidance from OIG
The Department of Health and Human Services Office of Inspector General recently issued its new General Compliance Program Guidance, the first of a series of compliance guidelines expected from the OIG, providing guidance, tools, and references addressed to federal healthcare program providers and suppliers. OIG makes clear that risk managers are an integral part of the effort.
-
‘Take Care of Maya’ Verdict Could Have Chilling Effect
A recent $261 million judgment against a hospital could have a chilling effect on hospitals trying to weigh the obligation to protect minor patients against the parents’ rights to see the child. The case received substantial media attention, which could influence the way clinicians and administrators handle such cases.
-
Infectious Disease Alert Updates
Smallpox Vaccination Effective Against Mpox; CLABSI Prevention
-
Rocky Mountain Spotted Fever: California and Mexico
The Centers for Disease Control and Prevention alerts clinicians to cases of Rocky Mountain spotted fever in southern California that had been acquired in Mexico.
-
Comparing Adjuvant Clindamycin to Linezolid for Invasive Group A Streptococcal Infections
In a retrospective, single-center cohort study of patients with severe group A streptococcal infection, there was no significant difference in clinical response in those treated with adjunctive clindamycin as compared with adjunctive linezolid
-
Imported Gestational Malaria
Pregnant women can develop malaria in non-endemic areas, even when they are far removed from malaria exposure both geographically and temporally.
-
ID Consultation Leads to Reduced Mortality from Gram-Negative Bacteremia
A multicenter, retrospective cohort study on patients with gram-negative bacteremia found infectious diseases consultation was associated with a 40% decrease in 30-day mortality.
-
2024 Resolution: Not to Be Replaced by a Machine
Chatbots, such as ChatGPT, are thought to have potential to eventually replace some straightforward infectious disease consultations. However, current technology does not yet instill confidence that the use of chatbots will be adequately accurate or safe for complex patient care. In addition, philosophical and ethical constraints raise doubt about the value of replacing specialist physician consultations.
-
Vonoprazan Fumarate Tablets (Voquezna)
The U.S. Food and Drug Administration has approved vonoprazan for the treatment of all grades of erosive esophagitis. Vonoprazan is a potassium-competitive acid blocker that originally was approved in 2022 for use in combination with amoxicillin or with amoxicillin and clarithromycin for the treatment of Helicobactor pylori infection.